Perrigo (PRGO) Other Non-Current Liabilities (2013 - 2026)

Perrigo's (PRGO) quarterly Other Non-Current Liabilities came in at $712.3 million in Q1 2026, up 31.54% year-on-year from $541.5 million in Q1 2025, and down 12.53% on a QoQ basis from $814.3 million in Q4 2025.

Perrigo (PRGO) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends

Perrigo (PRGO) has 14 years of Other Non-Current Liabilities data on file, last reported at $712.3 million in Q1 2026.

  • On a quarterly basis, Other Non-Current Liabilities rose 31.54% year-over-year to $712.3 million in Q1 2026; TTM through Mar 2026 was $712.3 million, a 31.54% increase from a year earlier, with the FY2025 full-year figure at $814.3 million, up 63.12% from the prior year.
  • Other Non-Current Liabilities for Q1 2026 stood at $712.3 million, down from $814.3 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for PRGO reached as high as $814.3 million in Q4 2025 and fell as low as $499.2 million in Q4 2024.
  • Historically, Other Non-Current Liabilities has averaged $614.7 million across 5 years, with a median of $613.9 million in 2023.
  • Across the five-year window, Other Non-Current Liabilities fell 18.72% in 2024 and jumped 63.12% in 2025, its largest moves.
  • Year by year, Other Non-Current Liabilities stood at $623.0 million in 2022, then dropped by 10.14% to $559.8 million in 2023, then decreased by 10.83% to $499.2 million in 2024, then soared by 63.12% to $814.3 million in 2025, then fell by 12.53% to $712.3 million in 2026.
  • Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $712.3 million in Q1 2026, $814.3 million in Q4 2025, and $689.7 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 Perrigo 1.40 Bn 1.05 Bn 325.50 Mn

Historic Data

Download Data
DateValue
Mar 28, 2026 712.30 Mn
Dec 31, 2025 814.30 Mn
Sep 27, 2025 689.70 Mn
Jun 28, 2025 673.40 Mn
Mar 29, 2025 541.50 Mn
Dec 31, 2024 499.20 Mn
Sep 28, 2024 660.30 Mn
Jun 29, 2024 535.40 Mn
Mar 30, 2024 526.20 Mn
Dec 31, 2023 559.80 Mn
Sep 30, 2023 613.90 Mn
Jul 1, 2023 658.70 Mn
Apr 1, 2023 637.60 Mn
Dec 31, 2022 623.00 Mn
Oct 1, 2022 573.20 Mn
Jul 2, 2022 577.00 Mn
Apr 2, 2022 554.20 Mn
Dec 31, 2021 530.10 Mn
Oct 2, 2021 565.80 Mn
Jul 3, 2021 554.00 Mn